To achieve capital growth.
Name | % Net Assets |
---|---|
Sanofi-Aventis | 4.5% |
Credit Suisse | 3.8% |
Novartis | 3.5% |
Total | 3.5% |
Roche | 3.3% |
Unilever | 3.3% |
Siemens | 3.2% |
Banco Santander | 3.2% |
Anheuser-Busch | 2.9% |
Zurich Financial Services | 2.8% |
Key | % Net Assets |
---|---|
Sanofi-Aventis | 4.5% |
Credit Suisse | 3.8% |
Novartis | 3.5% |
Total | 3.5% |
Other | 84.7% |
Date | 21-Nov-2024 |
---|---|
NAV | 954.00p |
Currency | GBP |
Change | -3.00p |
% | -0.31% |
YTD change | -15.50p |
YTD % | -1.60% |
Fund Inception | 27/08/1986 |
---|---|
Fund Manager | Aaron Barnfather / Mark Little and team |
TER | 1.07 (31-Mar-2014) |
Minimum Investment | |
---|---|
Initial | £200000 |
Additional | £500 |
Savings | £75 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.06 |
You are here: research